Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

52 Week Extension: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder

Next Previous
X
Search
Trial Profile

52 Week Extension: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vibegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 21 May 2018 Results of this optional 52 week extension reporting long-term safety and efficacy data, presented at the 113th Annual Meeting of the American Urological Association.
    • 11 Oct 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 23 Apr 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top